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https://doi.org/10.1016/j.xcrm.2021.100204SUMMARYT cells are involved in control of SARS-CoV-2 infection. To establish the patterns of immunodominance of
different SARS-CoV-2 antigens and precisely measure virus-specific CD4+ and CD8+ T cells, we study
epitope-specific T cell responses of 99 convalescent coronavirus disease 2019 (COVID-19) cases. The
SARS-CoV-2 proteome is probed using 1,925 peptides spanning the entire genome, ensuring an unbiased
coverage of human leukocyte antigen (HLA) alleles for class II responses. For HLA class I, we study an addi-
tional 5,600 predicted binding epitopes for 28 prominent HLA class I alleles, accounting for wide global
coverage. We identify several hundred HLA-restricted SARS-CoV-2-derived epitopes. Distinct patterns of
immunodominance are observed, which differ for CD4+ T cells, CD8+ T cells, and antibodies. The class I
and class II epitopes are combined into epitope megapools to facilitate identification and quantification of
SARS-CoV-2-specific CD4+ and CD8+ T cells.INTRODUCTION
The severity of the associated coronavirus disease 2019
(COVID-19) ranges from asymptomatic or mild self-limiting dis-
ease to severe pneumonia and acute respiratory distress
syndrome (World Health Organization [WHO]; https://www.
who.int/publications/i/item/clinical-management-of-covid-19).
We and others have started to delineate the role of SARS-CoV-2-
specific T cell immunity in COVID-19 clinical outcomes.1–8 A
growing body of evidence points to a key role for SARS-CoV-
2-specific T cell responses in COVID-19 disease resolution and
modulation of disease severity.2,6,9 Milder cases of acute
COVID-19 were associated with coordinated antibody, CD4+
and CD8+ T cell responses, whereas severe cases correlated
with a lack of coordination of cellular and antibody responses
and delayed kinetics of adaptive responses.2,6
To date, most studies have utilized pools of predicted or
overlapping peptides spanning the sequence of different
SARS-CoV-2 antigens,1,2,5–10 but the exact T cell epitopes and
immunodominant antigen regions have not been comprehen-
sively determined. Several studies have mapped different epi-
topes or the corresponding T cell receptors (TCRs), providing
important insights into the frequency and phenotype ofCell Repo
This is an open access article under the CC BY-Nepitope-specific CD8+ and CD4+ T cells in COVID-19 using
ex vivo studies,4,10–12 but have been biased in their approach
due to sampling only a limited number of cells,7,11,13 using hu-
man leukocyte antigen (HLA) predictions focused on a limited
number of allelic variants not representative of the majority of
the human population,11,13 or detecting responses mediated
by only a few cytokines, potentially largely underestimating total
responses.4,13 Other important studies, although providing crit-
ical knowledge about T cell recognition per se, utilize in vitro
re-stimulation protocols.13,14
Defining a comprehensive set of epitope specificities is impor-
tant for several reasons. First, it allows us to determine whether,
within different SARS-CoV-2 antigens, certain regions are immu-
nodominant. This will be important for vaccine design so as to
ensure that vaccine constructs include not only regions targeted
by neutralizing antibodies, such as the receptor binding domain
(RBD) in the spike (S) region, but also include regions capable of
delivering sufficient T cell help and are suitable targets of CD4+
T cell activity. Second, a comprehensive set of epitopes helps
define the breadth of responses in terms of the average number
of different CD4+ and CD8+ T cell SARS-CoV-2 epitopes gener-
ally recognized by each individual. This is key because some re-
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from immune recognition via accumulated mutations that can
occur during replication or through viral reassortment. Third, a
comprehensive survey of epitopes restricted by a set of different
HLAs representative of the diversity present in the general pop-
ulation is important to ensure that results obtained are generally
applicable across different ethnicities and racial groups and also
to lay the foundations to examine the potential associations of
certain HLAs with COVID-19 severity. Finally, the definition of
the epitopes recognized in SARS-CoV-2 infection is relevant in
the context of the debate on the potential influence of SARS-
CoV-2 cross-reactivity with endemic ‘‘common cold’’ coronavi-
ruses (CCC).3,4 Several studies have defined the repertoire of
SARS-CoV-2 epitopes recognized in unexposed individ-
uals,3,14,15 but the correspondence between that repertoire
and the epitope repertoire elicited by SARS-CoV-2 infection
has not been evaluated.
In this study, we report a comprehensive map of epitopes
recognized by CD4+ and CD8+ T cell responses across the entire
SARS-CoV-2 viral proteome. Importantly, these epitopes have
been characterized in the context of a broad set of HLA alleles
using a direct ex vivo, cytokine-independent approach.
RESULTS
Characteristics of the study participants
To broadly define the pattern of immunodominance and epitope
recognition associated with SARS-CoV-2 infection, we studied
peripheral blood mononuclear cell (PBMC) samples from 99
adult convalescent COVID-19 donors. Their age ranged from
19 to 91 years (median 41), with a gender ratio of about 2M:3F
(male 41%; female 59%). Ethnic breakdown was reflective of
the demographics of the local enrolled population. Samples
were obtained 3 to 184 days post-symptom onset (median
67 days). Peak COVID-19 disease severity was representative
of the distribution observed in the general population to date
(mild 91%; moderate 2%; severe and critical 7%; Table S1).
SARS-CoV-2 infection was determined by PCR-based testing
during the acute phase of infection, if available (79% of the
cases), and/or verified by plasma SARS-CoV-2 S protein RBD
immunoglobulin G (IgG) ELISA16 using plasma from convales-
cent phase blood draws. All donors were seropositive at the
time of blood donation, with the exception of two mildly symp-
tomatic donors with positive PCR results from the acute phase
of illness but seronegative results at time of blood donation (at
55 and 148 days post-symptom onset [PSO], respectively).
All donors were HLA typed at both class I and class II loci (Ta-
ble S2). The HLA class I and II alleles frequently observed in the
enrolled cohort were largely reflective of what is found in the
worldwide population, as reported by the Allele Frequency Net
Database17 and as retrieved from the Immune Epitope Data-
base’s (IEDB) (http://www.iedb.org) population coverage tool
(Figure S1).18,19 Of the 20 different HLA class I alleles with
phenotypic frequencies >5% in our cohort, 15 (75%) are also
present in the most common and representative class I alleles
in the worldwide population (Figures S1A and S1B).20 Likewise,
of the 34 different HLA class II alleles with phenotypic fre-
quencies >5% in our cohort, 26 (76%) are also present in the2 Cell Reports Medicine 2, 100204, February 16, 2021worldwide population with frequencies >5%. These alleles
correspond to 16 of the 27 (59%) alleles included in a reference
panel of the most common and representative class II alleles in
the general population (Figures S1D–S1F).21 In conclusion, our
cohort is largely representative of the HLA allelic variants
commonly expressed worldwide.
Pattern of antigen immunodominance in CD4+ and CD8+
T cell responses to SARS-CoV-2 antigens
To study adaptive immune responses in COVID-19 convalescent
donors, we previously utilized TCR-dependent activation
induced marker (AIM) assays to quantify SARS-CoV-2-specific
CD4+ and CD8+ T cells utilizing the combination of markers
OX40+CD137+ and CD69+CD137+ for CD4+ and CD8+ T cells,
respectively.1,6,15 To define the global pattern of immunodomi-
nance in the study cohort, we tested PBMCs from each donor
with sets of overlapping peptides spanning the various SARS-
CoV-2 proteins, as previously described (Figures 1A and 1B).1
These data also defined the specific viral antigens recognized
by each donor and therefore highlight the specific antigens/
donor pairs suitable for further epitope identification studies,
as shown in Figures 1C and 1E.
For each SARS-CoV-2 protein antigen (Table S3), we recorded
the % of donors in which a positive response was detected and
the total response counts (positive cells/million detected in the
AIM assay). This information was used to tabulate the percent-
age of the total response ascribed to each protein and calculate
the cumulative coverage provided by themost immunodominant
proteins.
For CD4+ T cell responses, 9 viral proteins (non-structural pro-
tein [nsp] 3, nsp4, nsp12, nsp13, S, open reading frame 3a
[ORF3a], membrane [M], ORF8, and nucleocapsid [N]) ac-
counted for 83% of the total response. In the context of CD8+
T cell responses, 8 viral proteins (nsp3, nsp4, nsp6, nsp12, S,
ORF3a, M, and N) accounted for 81% of the total response.
These results confirmed the pattern previously observed with a
more limited (n = 20) number of COVID-19 patients1 and highlight
a broad pattern of immunodominance, where 8 to 9 antigens are
required to cover 80% of the response.
We further evaluated the number of antigens recognized in
each of the individual donors analyzed. To this end, we focused
on antigens associated with a sizeable response, arbitrarily
defined herein as those antigens individually accounting for at
least 10% of the total response. We found that, per donor, an
average of 3.2 and 2.7 proteins were recognized by 10% or
more of the total CD4+ and CD8+ SARS-CoV-2-specific T cells,
respectively (Figures 1D and 1F).
Functional consequences of SARS-CoV-2-specific CD4+
T cell responses directed against different antigens
We next investigated whether the recognition of different SARS-
CoV-2 antigens by CD4+ T cells correlated with functional anti-
body and/or CD8+ T cell responses. Consistent with the wide
range of blood collection time points (day PSO) and peak dis-
ease severity in the COVID-19 donor cohort, we observed a
wide range of RBD IgG responses (Figure 2A). Combined
CD4+ T cell responses did not significantly correlate with the
antibody response to RBD (R = 0.1285; p = 0.2051; Figure 2B).
Figure 1. SARS-CoV-2-specific T cell reactivity per protein
PBMCs from convalescent COVID-19 donors (n = 99) were analyzed for reactivity against SARS-CoV-2 (A–F). Heatmaps of T cell reactivity across the entire
SARS-CoV-2 proteome and as a function of the donor tested are shown for CD4+ (A) and CD8+ (B) T cells. The x axis shows individual donors’ responses to the
indicated SARS-CoV-2 protein. Immunodominance at the ORF/antigen level and breath of T cell responses are shown for CD4+ (C) and CD8+ (E) T cells. Data are
shown as geometric mean ± geometric SD. The numbers of donors recognizing one or more antigens with a response >10%, normalized per donor to account for
the differences in magnitude based on days PSO, are shown for CD4+ (D) and CD8+ (F) T cells. Empty blue and red circles represent CD4+ and CD8+ T cell
reactivity per protein, respectively. Filled blue and red circles highlight the immunodominant antigens recognized by CD4+ and CD8+ T cells, respectively.
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that two correlations had p < 0.05, namely spike (R = 0.2223;
p = 0.0270) and M protein (R = 0.2117; p = 0.0354), but these
would not be significant when performing a multiple hypothesis
comparison taking all other antigens into account (Figures 2C–
2E). In contrast, the correlation between CD4+ and CD8+ T cellresponses was highly significant in aggregate (R = 0.6756; p =
1.70 3 1014; Figure 2F) and was significant for each of the in-
dividual antigen comparisons (Figures 2G–2I). The same was
observed when the correlations of the matched protein-specific
CD4+ and CD8+ T cell responses were considered (Figures
S2A–S2C).Cell Reports Medicine 2, 100204, February 16, 2021 3
Figure 2. SARS-CoV-2-specific CD4+ T cell reactivities and their correlations with antibody production and CD8+ T cell reactivity
(A) RBD IgG serology is shown for all the convalescent COVID-19 donors (n = 99) of this cohort.
(B–E) Serology data of (A) are correlated with CD4+ T cell reactivities specific against all combined proteins (B), structural proteins S, M, and N (C), non-structural
proteins nsp3, nsp4, nsp12, and nsp13 (D), and ORF8 and ORF3a (E).
(F–I) The total CD8+ T cell reactivity is correlated with the total CD4+ T cell reactivity (F) and the CD4+ T cell reactivity against structural proteins S, M, and N (G),
non-structural proteins nsp3, nsp4, nsp12, and nsp13 (H), and ORF8 and ORF3a (I).
Empty and filled circles represent correlation betweenCD4+ T cell reactivity and serology or CD8+ T cell reactivity, respectively. All analyseswere performed using
Spearman correlation, and the p values shown were not corrected for multiple hypothesis testing.
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against all dominant antigens is potentially relevant in terms of
providing helper function for CD8+ T-cell-specific responses.
However, it cannot be excluded that what we observed is due
only to the CD4+ T cell help or to other extrinsic and intrinsic
properties of antigen presentation and responsiveness within
an individual. This might reflect that T cell responses correlate
with gene expression. S, N, and M may be immunodominant
because of the very high gene expression for each.22 In this
context, it is perhaps surprising that a strong CD4+ and CD8+
T cell response was elicited by nsp3, which is not known to be
expressed at high levels.22
SARS-CoV-2 peptides and epitope screening strategy
The analysis of the SARS-CoV-2 proteome summarized above
identified the major viral antigens accounting for 80% or more
of the total CD4+ and CD8+ T cell response. These antigens
were then introduced into the epitope screening pipeline (Fig-
ure S3A). Because class II epitope prediction is not as robust
as class I prediction,23 and because of the high degree of overlap
in binding capacity of different HLA class II alleles, to determine
CD4+ T cell reactivity in more detail, we followed a comprehen-
sive and unbiased approach based on the use of complete
sets of overlapping peptides spanning each antigen and compo-
sition of antigen-specific peptide pools. Positivity was defined as
net AIM+ counts (background subtracted by the average of trip-
licate negative controls) >100 and a stimulation index (SI) > 2, as
previously described.24 Positive peptide pools were deconvo-
luted to identify the specific 15-mer peptide(s) recognized. For
large proteins, such as S, an intermediate ‘‘mesopool’’ step
was used to optimize use of reagents.
In parallel, we synthesized panels of predicted HLA class I
binders for the 28 most common allelic variants (Table S4),
as described in the STAR methods section. The top two hun-
dred predicted peptides were synthesized for each allele, lead-
ing to 5,600 predicted HLA binders in total. To identify CD8+
T cell epitopes, we tested individual peptides derived from
the specific antigen(s) recognized by CD8+ T cells of individual
donors and that were predicted to bind the HLA class I alleles
expressed by the respective donor (Figures 1B and 1E). To
quantify the population coverage provided by the HLA class I
alleles selected for study, we tabulated the fraction of the
donor cohort studied where allele matches were identified for
0, 1, 2, 3, or 4 of the respective HLA A and B alleles expressed
by the donor. We found that 98% of the participants in our
cohort were covered by at least one allele, 91% by 2 or
more, and 74% were covered by 3 or more of the alleles in
our panel (Figure S1C). As shown in Table S3, focusing on
the 8 most dominant SARS-CoV-2 antigens for the purpose
of epitope identification allowed mapping of 80% or more of
the response, although screening only 35%–40% of the total
peptides.
To broadly identify T cell epitopes recognized in a cytokine-in-
dependent manner, we used the AIM assay mentioned
above.1,25 Examples of gating strategies, pool deconvolution,
and epitope identification for both CD4+ and CD8+ T cell re-
sponses are shown in Figure S3B. AIM+ cell counts were calcu-
lated per million CD4+ or CD8+ T cells, respectively.Summary of CD4+ T cell epitope identification results
To identify specific CD4+ T cell epitopes, we deconvoluted
peptide pools corresponding to antigens previously identified
as positive for CD4+ T cell activity in each specific donor (Fig-
ure 1A). In instances where not all positive pools could be de-
convoluted due to limited cell availability, peptide pools were
selected for screening to ensure that each of the 9 major an-
tigens was tested in at least 10 donors. Overall, we were
able to test each peptide for these antigens in a median of
13 donors (range 10–17). Each donor was previously deter-
mined to be positive for CD4+ T cell responses to that specific
antigen.
Taken together, a total of 280 SARS-CoV-2 CD4+ T cell epi-
topes were identified, including 3 nsp16 (this protein was not
included in the top proteins studied) epitopes identified in par-
allel experiments in 2 donors (Table S5). We found that each
donor responded to an average of 3.2 viral antigens (Fig-
ure 1D), and 5.9 CD4+ T cell epitopes were recognized per an-
tigen for the top 80% most immunodominant antigens (data
not shown). For each epitope/responding donor combination,
potential HLA restrictions were also inferred based on the pre-
dicted HLA binding capacity of the epitope for the HLA alleles
present in the respective responding donor (listed in Table S2),
as previously described (Voic et al., 2020).15,26 Table S6 pro-
vides the spectrum of distributions of the magnitudes of
T cell responses to all peptides tested at the level of the indi-
vidual donors.
HLA binding capacity of dominant epitopes
A total of 109 of the 280 epitopes were recognized by 2 or more
donors, accounting for 71% of the total response. The 49 most
dominant epitopes, recognized in 3 or more donors, accounted
for 45% of the total response (Figure 3A).
Because dominant epitopes are associated with promiscu-
ous HLA class II binding,27,28 defined as the capacity to bind
multiple HLA allelic variants, we investigated the role of HLA
binding in determining immunodominant SARS-CoV-2 epi-
topes. Specifically, we measured the in vitro binding capacity
of the 49 most dominant epitopes (positive in 3 or more do-
nors, as mentioned above) for a panel of 15 of the most com-
mon DR alleles using individual peptides and purified HLA
class II molecules.29 The results are provided in Table S7. It
was noted that, in general, a good correlation was observed
between predicted and measured binding (R = 0.6604; p =
2.97 3 1093; Figure S4A). Based on these results, we further
characterized those 49 most dominant epitopes using pre-
dicted binding for additional HLA class II alleles, including a
panel of the 12 most common HLA-DQ and DP allelic variants,
and all HLA class II variants (DR, DQ, and DP) expressed in the
cohort.
Overall, the 49 most dominant epitopes showed signifi-
cantly higher binding promiscuity (number of alleles bound
at the 1,000 nM or better threshold)30,31 for the panel of com-
mon HLA class II than a control group of 49 non-epitopes
derived from the same proteins (average number of HLA pre-
dicted to be bind ± SD epitopes = 10.8 ± 6.5; non-epitopes =
5.7 ± 6; p = 0.0001 by Mann-Whitney; Figures S4B and S4C).
The same conclusion was reached when the full set of HLACell Reports Medicine 2, 100204, February 16, 2021 5
Figure 3. Heat maps of HLA predicted binding patterns in the 27 most frequent HLA class II alleles
(A) SARS-CoV-2 CD4+ T cell epitopes as a function of the number of responding donors (n = 44 convalescent COVID-19 donors) recognized and strength of
responses.
(B and C) Predicted binding patterns for the top 49 most immunodominant SARS-CoV-2 CD4+ T cell epitopes (B) are compared with a set of matched non-
epitopes (C). Predicted half maximal inhibitory concentration (IC50) was calculated using NetMHCIIpan and converted to log10 scale. Lower values indicate




OPEN ACCESSalleles present in the cohort was considered using the same
criteria (average ± SD epitopes = 24.3 ± 15.2; non-epitopes =
13.2 ± 14.1; p = 0.0003 by Mann-Whitney; Figures S4D and
S4E).
Heatmaps of the 49 epitopes and non-epitopes considering
the panel of common HLA DR, DP, and DQ are shown in Figures
3B and 3C. These results confirm that broad HLA binding capac-
ity is a key feature of dominant epitopes. It further indicates that,
because of their broad binding capacity, these epitopes are likely6 Cell Reports Medicine 2, 100204, February 16, 2021to be recognized in different geographical settings and different
ethnicities.
Similarity of SARS-CoV-2 CD4+ T cell epitopes to CCC
sequences
Several studies have reported significant pre-existing immune
memory to SARS-CoV-2 peptides in unexposed donors.1,3,4,15
This reactivity was shown to be associated, at least in some in-
stances, with memory T cells specific for human CCCs cross-
Figure 4. Distribution of SARS-CoV-2 CD8+ T cell responses by antigen and class I allele
(A) The number of donors testedwith their HLA-matched class I peptides for each of the 8 dominant proteins for CD8+ (n = 40 convalescent COVID-19 donors with
a range of 4 to 35 donors tested per protein).
(B and C) The distribution of allele-specific CD8+ responses for the 18 class I alleles that were tested in 3 or more donors is shown as function of protein
composition (B) or the HLA class I alleles tested (C). Blue bars represent the total magnitude of AIM+ CD8+ T cells divided by the number of positive donors. Gray
bars represent the frequency of positive tests.
(D) The total number of epitopes identified for each class I allele is shown in panel.
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it was shown that the SARS-CoV-2 epitopes recognized in unex-
posed donors had significantly higher homology to CCC than
SARS-CoV-2 sequences not recognized in unexposed donors.
Here, using the exact same methodology,15 we performed the
converse analysis, namely an analysis of the homology between
the CD4+ T cell epitopes experimentally identified in COVID-19
donors (Figure S5) and sequences of peptides derived from
the four widely circulating human CCCs (NL63, OC43, HKU1,
and 229E). No significant differences were observed based on
percent sequence identity between epitopes recognized from
the COVID-19 cohorts and non-epitope controls in structural
proteins S, M, and N and accessory proteins encoded by
ORF3a and ORF8 or non-structural proteins (Figure S5A).
Indeed, in our previous studies,1,15 we noted that the pattern of
antigen recognition in exposed and unexposed donors was
significantly different. Here, having defined the actual epitopes
recognized in COVID-19, we compared them to the epitopes
previously identified in unexposed donors. The present study
re-identified 50% of the epitopes in our COVID-19 cohort but
in addition identified 227 CD4+ T cell epitopes specific for
SARS-CoV-2 infection (Figure S5C). Thus, more than 80%
(227/280) of the epitopes identified herein were not previously
seen in the unexposed cohort. These results are consistent
with the notion that, although a cross-reactive repertoire is pre-
sent in unexposed donors, SARS-CoV-2 infection elicits a vast
repertoire of additional T cell specificities.Summary of CD8+ T cell epitope identification results
Following the approach described above, a total of 523 SARS-
CoV-2 CD8+ T cell epitopes were identified (Table S8). These
epitopes are associated with 26 different HLA restrictions, based
on predicted HLA binding capacity matched to the HLA alleles of
the responding donor. A complete list of the synthesized class I
peptides and the corresponding magnitude of T cell responses
for individual donors can be found in Table S6. For eight HLAs,
only 1 to 2 donors expressing thematching HLA could be tested.
Predicted binders for the remaining 18 HLAs were tested in a
median of 5 donors (range 3–9). The 8 most immunodominant
proteins were screened in an average of 19 donors (range 4–
35; Figure 4A). Of the 523 CD8+ T cell epitopes identified, 61
were recognized in 2 or 3 different donor-allele combinations,
meaning that there were 454 unique peptides recognized. Of
these, 101 (22%)were recognized by 2 ormore donors, account-
ing for 49% of the total response. We found that each donor
recognized an average of 2.7 antigens (Figure 1F) and responded
to an average of 1.6 CD8+ T cell epitopes per antigen per HLA
allele (data not shown). Considering 4 HLA A and B alleles in
each donor, we expect at least 17 epitopes per donor for class
I (2.7 3 1.6 3 4 = 17.3).
Figure 4 shows the frequency of positive epitopes (identified
epitopes/peptides screened), and the average magnitude of
epitope responses (total magnitude of response normalized by
the number of positive donors), as a function of protein (Fig-
ure 4B) or HLA class I allele (Figure 4C) analyzed. Each HLACell Reports Medicine 2, 100204, February 16, 2021 7
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dian 24; Figure 4D). Interestingly, as also previously detected in
other systems,32,33 there was a wide variation as a function of
HLA allele. Some alleles, such as A*03:01 and A*32:01, were
associated with responses that were both infrequent and
weak; in other cases (e.g., A*01:01), responses were infrequent
but when observed were of high magnitude. Finally, and
conversely, other alleles were associated with relatively frequent
but low-magnitude responses (e.g., A*68:01). This effect was
previously linked to differences in the size of peptide repertoires
associated with different HLA motifs.20
In terms of antigen specificity of CD8+ T cell responses, rela-
tively similar epitope-specific response frequencies were
observed for the various antigens, with the exception of nsp12,
which was associated with responses of low frequency and
magnitude (Figure 4B). These results should be interpreted with
the caveat in mind that the donors screened were pre-selected
on the basis of association with positive responses to that partic-
ular antigen; thus, these data do not directly address protein im-
munodominance, which is instead addressed in Table S3. These
data instead point to the relative frequency and magnitude of re-
sponses at the level of individual epitopes associatedwith a given
antigen, which were found to be overall similar.
To address the potential relationship between CD8+ T cell
epitope recognition and CCC homology, as performed above
in the case of CD4+ T cell epitopes, we analyzed the homology
of the CD8+ T cell epitopes to CCCs (NL63, OC43, HKU1, and
229E), as compared to the homolog to the sameCCC viruses de-
tected in the case of peptides that tested negative in all donors
tested, regardless of the HLA restriction (Figure S5). Similar to
what was observed in the context of CD4+ T cell responses,
the CD8+ T cell epitopes recognized in convalescent COVID-
19 donors were not associated with higher sequence identity
to CCC as compared to non-epitopes when structural, acces-
sory, or non-structural proteins (Figure S5B) were considered.
Distribution of CD4+ and CD8+ T cell epitopes within
dominant SARS-CoV-2 antigens
We next analyzed the distribution of CD4+ and CD8+ T cell epi-
topes within the dominant SARS-CoV-2 S, N, and M antigens
(Figure 5). For each antigen, we show the frequency (red line)
and magnitude (black line) of CD4+ T cell responses along the
antigen sequence, considering regions with response frequency
above 20% as immunodominant. Based on the results pre-
sented above, we also plotted HLA class II binding promiscuity
(defined as the number of HLA allelic variants expressed in the
donor cohort predicted to be bound by a given peptide) and
the degree of homology of each 15-mer peptide for aligned
CCC antigen sequences. The bottom panel represents the distri-
bution of CD8+ T cell epitopes (black) and non-epitopes (red)
along the antigen sequence.
Responses to S peptides with a frequency of 20% or higher
were focused on discrete regions of the protein involving the
N-terminal domain (NTD), the C-terminal (CT) 686–816 region,
and the neighboring fusion protein (FP) region; only a few re-
sponses were focused on the RBD. These immunodominant re-
gions are boxed in red in Figure 5A. We expected HLA-binding
capacity to be associated with T cell immunodominant regions8 Cell Reports Medicine 2, 100204, February 16, 2021and indeed found a significant positive correlation with the fre-
quency of responses (R = 0.2231; p = 0.0003 by Spearman cor-
relation; Figure S5D). No significant correlation (R = 0.03144;
p = 0.6187 by Spearman correlation; Figure S5E) was found
with sequence homology to CCC (calculated as maximum
sequence homology to the four main CCC species). As indicated
in the 3D rendering of the S crystal structure (PDB: 6XR8), these
immunodominant regions were mostly located in the surface-
exposed portions of the S monomer and were not particularly
influenced by the glycosylation pattern (shown in Figure 5A as
stars in the linear structure description and based on experi-
mental identification by Cai and co-authors34). The glycosylation
patterns are also shown in the 3D rendering of the corresponding
crystal structure, based on curation done by the authors of the
same manuscript, and shown as gray dots (Figure 6A). We
further explored the correlation between CD4+ T cell immunodo-
minance and location of proteolytic cleavage sites, utilizing the
major histocompatibility complex class II (MHCII)-NP algo-
rithm.35 The results did not reveal any significant correlation be-
tween the predicted cleavage sites and immunodominant re-
gions (Spearman correlation has R = 0.08426 and p =
0.1816; Figure S5F). This is consistent with previous results
that indicated that predicted cleavage sites do not significantly
improve epitope predictions.35 Finally, CD8+ T cell reactivity
did not reveal any particular immunodominant region in S, with
epitopes and non-epitopes roughly equally distributed along
the sequence (Figure 5A).
In the sameway, we compared responses observed within the
N andM proteins as a function of structural protein composition,
HLA promiscuity, and CCC homology (Figures 5B, 5C, 6B, and
6C). For the N protein (Figure 5B), the majority of the response
was focused on the NTD and CTD regions, with lower contribu-
tions from the linker region (all outlined in red boxes); segments in
themiddle and toward the ends of the protein were devoid of any
reactivity. The correlation between immunodominance and HLA
binding promiscuity was even stronger than observed for S (R =
0.4725; p = 7.41 3 106; Figure S5G). Similar to what was
observed for the S protein, no significant correlation between
the frequency of positive responses was observed with CCC
similarity (R = 0.1660; p = 0.1362; Figure S5H) or predicted cleav-
age sites (R = 0.009245; p = 0.9343; Figure S5I). The immuno-
dominance of N-specific CD8+ T cell responses mirrors the one
observed for the CD4+ T cell counterpart, highlighting that, in
general, the N-terminal and C-terminal domains are the major
immunodominant regions of N recognized by both T cell types.
CD4+ T cell immunogenic regions were distributed across the
entire span of the M protein (Figure 5C), including the transmem-
brane region (Figure 6C). No significant correlation was observed
when investigating HLA binding promiscuity (R = 0.2374; p =
0.1253; Figure S5J), CCC similarity (R = 0.07648; p = 0.6259; Fig-
ureS5K), orpredictedcleavagesites (R=0.08421;p=0.5913;Fig-
ure S5L). The lack of correlation between M epitopes and HLA
binding is consistent with the interpretation that M is a prominent
antigen because it is highly expressed, not because it contains
high-quality epitopes. No particular immunodominance patterns
were observed for the M protein with respect to CD8+ epitopes.
Finally, when we investigated the location of immunodomi-
nant T cell regions relative to the main sites identified for
Figure 5. Immunodominant regions for CD4+ T cells S, N, and M proteins.
(A) S, (B) N, and (C) M proteins as a function of the frequency of positive response (red) and total magnitude (black) in the topmost panel. The dotted red line
indicates the cutoff of 20% frequency of positivity used to define the immunodominant regions boxed in red and also shown in red in Figure 6. The x axis labels in
this topmost panel indicate themiddle position of the peptide. Binding promiscuity was calculated based on NetMHCIIpan predicted IC50 for the alleles present in
the cohort of donors tested and is shown in gray on the upper middle panel. The lower middle panel shows the % homology of SARS-CoV-2 to the four most
frequent CCC (229E in pink, NL63 in green, HKU1 in orange, and OC43 in black) and the max value (blue). The linear structure of each protein is drawn below the
graph of homology. The magnitude of CD8+ responses to class I predicted epitopes is shown in the bottom panel, where black dots represent epitopes and red
dots represent non-epitopes, each centered on themiddle position of the peptide. PBMCs from convalescent COVID-19 donors (n = 44) were tested for reactivity
to the peptides indicated in the topmost and bottommost panels (A)–(C).
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identified in S and N showed minimal overlap with immunodo-
minant linear regions targeted by antibody responses (Figure 6).
The CD4+ T cell epitope recognition patterns of ORF3a, ORF8,
nsp3, nsp4, nsp12, and nsp13 are shown in Figure S6. The
ORF8 protein was similar to M in that epitopes throughout
both of these small proteins were recognized. ORF3a had clear
regions of response clustered in the middle and at the C termi-
nus. Nsp3, which was the 4th most immunodominant antigen,was associated with a rather striking immunodominant region
centered around residue 1,643. Other non-structural proteins
were less immunodominant overall but had discreet regions tar-
geted by CD4+ T cell responses (i.e., residue 5,253 for nsp12).
Reactivity of megapools based on the experimentally
identified epitopes
The experiments described above identified a total of 280 CD4+
and 454 CD8+ T cell epitopes. These epitopes were arrangedCell Reports Medicine 2, 100204, February 16, 2021 9
Figure 6. Immunodominant regions for CD4+
T cells and B cells in relation to the 3D
rendering of S, N, and M proteins
3D rendering of S (A), N (B), and M (C) proteins. The
drawings show in gray the 3D structures, in red the
CD4+ T cell immunodominant regions for each
protein with frequency of positive responses >20%
(also shown in red in Figure 5), and in yellow the B
cell immunodominant regions for each protein
based on the work of Shrock et al.36 Glycosylation
sites for S are shown as gray dots and are based on
information embedded in the original crystal struc-
ture shown to map the immunodominant regions
(PDB: 6XR8).
(A) The S protein is shown as monomer on the left
and trimer in the middle and on the right (side and
top views).
(B) N protein 3D rendering was based on a model
generated using Phyre2. Additional details about
the N model are available in the STAR methods
section.
(C) The M protein is shown as amonomer according
to a model previously described by Heo et al.37
All the 3D renderings have been performed using
the free version of YASARA.
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tively (where the E denotes ‘‘experimentally defined’’). These
MPs were tested in a new cohort of 31 COVID-19 convalescent
donors (none of these donors were utilized in the epitope identi-
fication experiments) and 25 unexposed controls (Table S1). MP
reactivity was assessed for all donors using AIM and interferon g
(IFNg) FluoroSpot assays.
To put the results in context, we also tested peptides con-
tained in the CD4-R and CD4-S and CD8-A and CD8-BMPs pre-
viously utilized to measure SARS-CoV-2 CD4+ and CD8+ T cell
responses, respectively.1,2,6,15 These MPs are based on either
overlapping peptides spanning the entire S sequence (CD4-S)
or predicted peptides (all other proteins). Although these pools
contain a larger total number of peptides (474 for CD4-R +
CD4-S and 628 for the CD8-A + CD8-B) than the corresponding
experimentally defined sets, we expected that the experimen-
tally defined peptide sets would be able to recapitulate the reac-
tivity observed with the previously utilized MPs. As a further
context, we also tested the T cell epitope compositions (ECs)
class I and EC class II pools of experimentally defined CD8+
and CD4+ epitopes described by Nelde et al.,14 encompassing
29 and 20 epitopes each, which prior to this study represented
the most comprehensive set of experimentally defined epitopes.
As might be expected, the results showed that the AIM assay
was more sensitive than the FluoroSpot assay (Figure 7). On the
other hand, as a tradeoff for the lower signal, the FluoroSpot
assay showed higher specificity in the responses detected,
with fewer unexposed individuals showing any reactivity
compared to the AIM assay. For CD4+ T cell responses as de-
tected in the AIM assay (Figure 7A), the CD4-E MP recapitulated
the reactivity observed with the MPs of larger numbers of pre-
dicted peptides (CD4-R+S) and showed significantly higher
reactivity (p = 4.30 3 106 by Mann-Whitney) as compared to
the EC class II pool. A similar picture was observed when the10 Cell Reports Medicine 2, 100204, February 16, 2021FluoroSpot assay was utilized (Figure 7B), with a significantly
higher reactivity of the CD4-E MP compared to the CD4-R+S
(p = 0.0208 by Mann-Whitney) and to the EC class II pool (p =
1.39 3 107 by Mann-Whitney). In both AIM and FluoroSpot as-
says, the CD4-EMP showed the highest capacity to discriminate
between COVID-19 convalescent and unexposed donors (p =
3.19 3 1010 and p = 1.56 3 109, respectively, by Mann-
Whitney).
A similar picture was noted in the case of CD8+ T cell reactivity
(Figures 7C and 7D), where the CD8-E MP recapitulated the
reactivity observed with the MPs of larger numbers of predicted
peptides (CD8-A+B), with a strong trend (p = 0.0551 by Mann-
Whitney) toward more reactivity than the EC class II pool. In
the case of the FluoroSpot assay, we noted equivalent reactivity
for the CD8-E and CD8-A+B MPs and significantly higher reac-
tivity (p = 0.0219 byMann-Whitney) than the EC class II pool (Fig-
ure 7D). In both assays, the CD8-E MP showed highest capacity
to discriminate between COVID-19 convalescent and unex-
posed subjects (p = 1.47 3 108 and p = 1.48 3 108, respec-
tively, by Mann-Whitney). To test how well the different T cell
responses measured separate individuals that have been
exposed to SARS-Cov-2 versus those that do not, we performed
receiver operating characteristic curve (ROC) analyses (Figures
7E–7H), which allow us to directly compare the classification
success based on true- and false-positive rates. The CD4-E
and CD8-E response data were associated with the best
performance.
Considering that a potential practical limitation in the charac-
terization of SARS-CoV-2 responses is the number of cells avail-
able for study, in selected COVID-19 donors, we titrated the
number of PBMCs/well to determine whether a response could
be measured with lower cell numbers. As expected, as the cell
input was decreased, the magnitude of responses decreased
correspondingly. Although marginal responses were seen with
Figure 7. T cell responses to SARS-CoV-2 megapools as measured in AIM (empty circles) and FluoroSpot (filled in circles) assays
(A–D) Twenty-five unexposed and 31 convalescent COVID-19 donors were tested in the AIM assays (A and C), and all donors were also tested in the FluoroSpot
assays (B and D).
(A and B) CD4+ T cell responses to CD4-R+S (previously described), CD4-E (280 class II epitopes identified in this study), and EC class II14 megapools were
measured via AIM (A) and FluoroSpot (B). Bars represent geometric mean ± geometric SD, and p values were calculated by Mann-Whitney.
(C and D) CD8+ T cell responses to CD8-A+B (previously described), CD8-E (454 class I epitopes identified in this study), and EC class I14 megapools were
measured via AIM (C) and FluoroSpot (D). Bars represent geometric mean ± geometric SD, and p values were calculated by Mann-Whitney.
(E–H) ROC analysis for CD4+ and CD8+ T cell response data in FluoroSpot (F–H) and AIM (E–G) assays.
(I–L) Additionally, we further tested 17 of these COVID-19 convalescent donors in FluoroSpot with a titration of 200, 50, 25, and 12.53 103 cells per well with the
indicated CD4-MPs (I and J) and CD8-MPs (K and L). (I and K) Bars represent geometric mean ± geometric SD, and p values were calculated by Mann-Whitney.
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able with 50,000 cells/well, with 8 out of 17 donors responding
for the CD4-E MP (as compared to 16 out of 17 in the case of
200,000 cell level). Similarly, in the case of the CD8-E MP, 8
out of 17 donors responded with 50,000 cells/well (as compared
to 11 out of 17 in the case of 200,000 cell level). The frequency
and magnitude of responses of CD4-E were higher compared
to the EC class II (p = 3.593 105 and p = 0.0044 by Mann-Whit-
ney; Figures 7I and 7J). The CD8-E MP was also associated with
a higher magnitude of response than the EC class I pool (Figures
7K and 7L). In conclusion, these results underline the biological
relevance of the more comprehensive CD4-E and CD8-E MPs.
DISCUSSION
This study presents a comprehensive analysis of the patterns of
epitope recognition associated with SARS-CoV-2 infection in a
cohort of approximately 100 different convalescent donors
spanning a range of peak COVID-19 disease severity represen-tative of the observed distribution in the San Diego area.
SARS-CoV-2 was probed using 1,925 different overlapping pep-
tides spanning the entire viral proteome, ensuring an unbiased
coverage of the different HLA class II alleles expressed in the
donor cohort. For HLA class I, we used an alternative approach,
selecting 5,600 predicted binders for 28 prominent HLA class I
alleles, representing 61% of the HLA A and B allelic variants in
the worldwide population, and affording an overall 98.8% HLA
class I coverage at the phenotypic level.
The biological relevance of the epitope characterization
studies summarized here is underlined by the use of the
ex vivo AIM assay that does not require in vitro stimulation, which
potentially skews the results by eliciting responses from naive
cells. The AIM assay is also more agnostic for different types
of CD4+ T cells, as it measures all activated cells, regardless of
T cell subset or any particular pattern of cytokine secretion.
We are not aware of any study that describes the repertoire of
CD4+ andCD8+ T cell epitopes recognized in SARS-CoV-2 infec-
tion with a comparable level of granularity or breadth. AlthoughCell Reports Medicine 2, 100204, February 16, 2021 11
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and accordingly represent very useful advances, these studies
either utilized in vitro expansion,14 were limited in the number of
proteins analyzed,4 characterized responses in fewer than 10
HLA types,10,11,14 or focused on TCR repertoire after in vitro
expansion of small numbers of cells.12 Comparing our results
with those obtained in those previous studies, we note that, of
the 20HLAclass II peptides identified byNelde andco-authors,14
14 were contained within proteins wemapped here in detail, and
we independently re-identified 12 (86%) of them (identical or
largely overlapping sequences). Of 137 class I peptides reported
thus far,10,11,14 98 were contained within the viral proteins we
mapped in detail, and we independently re-identified 68 (69%)
of them (identical or largely overlapping sequences).
Importantly, because SARS-CoV-2 antigen-specific T cell re-
sponses were evaluated in a systematic and unbiased fashion,
quantitative estimates of the size of the repertoire of T cell
epitope specificities recognized in each donor can be derived.
Determining the breadth of responses is of relevance, because
previous studies11,12 have suggested narrow SARS-CoV-2-spe-
cific T cell repertoires in COVID-19 patients; notably, a limited
repertoire could favor viral mutation, a particular concern with
this RNA virus. Based on our results, we expect that each donor
would be able to recognize about 19 CD4+ T cell epitopes, on
average. Likewise, for CD8+ T cells, we expect at least 17 epi-
topes per donor to be recognized. Overall, T cell responses in
SARS-CoV-2 are estimated to recognize even more epitopes
per donor than seen in the context of other RNA viruses, such
as dengue,38,39 where 11.6 and 7 CD4+ and CD8+ T cell epi-
topes, respectively, were recognized on average. This analysis
should allay concerns over the potential for SARS-CoV-2 to
escape T cell recognition by mutation of a few key viral epitopes.
We defined the patterns of immunodominance across the
various antigens encoded in the SARS-CoV-2 genome recog-
nized in COVID-19 donors. Consistent with earlier reports from
our group1 and others,10 we see clear patterns of immunodomi-
nance, with a limited number of antigens accounting for about
80% of the total response. In general, the same antigens are
dominant for both CD4+ and CD8+ responses, with some differ-
ences in relative ranking, such as in the case of nsp3, which is
relatively more dominant for CD8+ than CD4+ T cell responses.
Immunodominance at the protein level correlated with protein
abundance/gene, as previously noted for CD4+ T cell re-
sponses,22 although we note that the accessory proteins and
nsps also account for a significant fraction of the response
despite their predicted lower abundance in infected cells.
Because of their role in instructing both antibody and CD8+
T cell responses,wecorrelatedCD4+Tcell activity on aper donor
and per antigen level with antibody and CD8+ T cell adaptive re-
sponses. This enabled establishing which antigens have func-
tional relevance in terms of eliciting CD4+ T cell responses corre-
lated with antibody and CD8+ T cell responses. At the level of
antibody responses, S andMwere correlated with RBD antibody
titers, highlighting their capacity to support antibody responses,
presumably by a deterministic linkage (viral antigen bridge) and
cognate interactions.40 Surprisingly, N-specific CD4+ T cell re-
sponses did not correlate with S RBD antibody titers, suggesting
unexpected complexity of the N-specific CD4+ T cell response.12 Cell Reports Medicine 2, 100204, February 16, 2021By contrast with these selective effects, CD4+ T cell activity
against any of the antigens correlated with the total CD8+ T cell
activity, suggesting that the role of CD4+ T cell responses driven
by the different proteins is determinant in its helper function for
either RBD-specific antibody production or CD8+ T cell re-
sponses. This was particularly true in both contexts when looking
specifically at the S and M proteins, which are also the strongest
and most frequently recognized antigens for both CD4+ and
CD8+ T cells.
After examining relative immunodominance at the level of the
different SARS-CoV-2 antigens, we probed for variables that
may influence which specific peptides are recognized within a
given antigen/ORF. Previously, we have shown that SARS-
CoV-2 sequences recognized in unexposed individuals were
associated with a higher degree of similarity to sequences en-
coded in the genome of various CCCs. Here, repeating the
same analysis with the SARS-CoV-2 epitopes recognized in
COVID-19 donors, we found no significant correlation. We
further show that although a large fraction of the epitopes previ-
ously identified in unexposed donors are re-identified in COVID-
19 donors, about 80% of the epitopes are not previously seen in
unexposed, suggesting that the SARS-CoV-2-specific T cell
repertoire of COVID-19 cases is overlapping but substantially
different from the SARS-CoV-2-cross-reactive memory T cell
repertoire of unexposed donors. This is consistent with our pre-
vious observation of a different pattern of reactivity15 and consis-
tent with reports from other groups.4,14
HLA binding capacity was a major determinant of immunoge-
nicity for CD4+ T cells (the influence of HLA binding was not eval-
uated for CD8+ T cell, because the tested epitope candidates
were picked based of their predicted HLA binding capacity).
As found in several previous large-scale, pathogen-derived
epitope identification studies, immunodominant epitopes were
also found to be promiscuous HLA class II binders.27,41 Binding
to multiple HLA allelic variants is an important mechanism to
amplify the potential immunogenicity of peptide epitopes and
specific regions within an antigen. It is possible that the domi-
nance of particular regions might further correlate with process-
ing. However, at this juncture, HLA class II processing algorithms
do not effectively predict epitope recognition.35,42,43
Further analysis projected the CD4+ T cell dominant regions on
known or predicted SARS-CoV-2 protein structures. This estab-
lished that the dominant epitope regions are different for B and
T cells. This is of relevance for vaccine development, as inclusion
of antigen sub-regions selected on the basis of dominance for
antibody reactivity might result in an immunogen devoid of suffi-
cient CD4+ T cell activity. In this context, it is important to note
that the RBD region had very few CD4+ T cell epitopes recog-
nized in COVID-19 donors, but inclusion of regions neighboring
the RBDN and C termini would be expected to provide sufficient
CD4+ T cell help.
In contrast to the clear demarcation of dominant regions for
antibody and CD4+ T cell responses, CD8+ T cell epitopes
were uniformly dispersed throughout the various antigens,
consistent with previous in-depth analyses revealing little posi-
tional effect in CD8+ T cell epitope distribution.44 In the case of
CD8+ T cell responses, our data highlight HLA-allele-specific dif-
ferences in the frequency and magnitude of responses. This
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to potential HLA-linked protective versus susceptibility effects.
The current study is not powered to test these potential effects,
leaving it to future studies to examine this possibility. Regard-
less, our study provides a roadmap for inclusion of specific
regions or discrete epitopes to allow for CD8+ T cell epitope rep-
resentation across a variety of different HLAs.
Finally, the functional relevance of our study was highlighted
by the generation of improved epitope MPs for measuring
T cell responses to SARS-CoV-2; these experimentally defined
pools are associated with increased activity and lower
complexity when compared to our previous MPs based on over-
lapping and predicted peptides. We plan to make these epitope
pools available to the scientific community at large and expect
that they will facilitate further investigation of the role of T cell im-
munity in SARS-CoV-2 infection and COVID-19.
In conclusion, we identify several hundred different HLA class I
and class II restricted SARS-CoV-2-derived epitopes. We antic-
ipate that these results will be of significant value in terms of
basic investigation of SARS-CoV-2 immune responses and in
the development of both multimeric staining reagents and T-
cell-based diagnostics. In addition, the results shed light on
the mechanisms of immunodominance of SARS-CoV-2, which
have implications for understanding host-virus interactions, as
well as for vaccine design.
Limitations of study
To maximize cell usage, our analysis was focused on the most
dominantly recognized proteins. Screening for less commonly
recognized proteins would require a larger cohort to enable iden-
tification of a sufficient number of donors responding to each
protein. However, such expanded studies would be expected
to yield additional epitopes.
The limited number of donors studied also did not allow inves-
tigation of responses directed against relatively rare HLA alleles,
and HLA restrictions were not experimentally verified. The pre-
dictions utilized for HLA class I included the top 200 candidates
for each allele. Utilizing more generous prediction thresholds is
likely to allow for identification of additional epitopes. The limited
number of donors also did not allow for the evaluation of poten-
tial differences in terms of ethnic background, disease severity,
age, and gender. Future investigations will include validation of
the epitope pools as potential diagnostic tools, establish a
robust, user-friendly T cell assay, and investigate differences in
T cell reactivity as a function of ethnicity, disease severity, age,
and gender.
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Data and code availability
The published article includes all data generated or analyzed during this study, and summarized in the accompanying tables, figures
and supplemental materials.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Convalescent COVID-19 Donors utilized for epitope identification
Blood donations from the 99 convalescent donors included in this study’s cohort were collected through either the UC San Diego
Health Clinic under IRB approved protocols (200236X), or under IRB approval (VD-214) at the La Jolla Institute. Donations obtained
through the CROs Sanguine, BioIVT and Stem Express were collected under the same IRB approval (VD-214) at the La Jolla Institute.
Details of this cohort can be found in Table S1. All donors were over the age of 18 years and no exclusions were made due to disease
severity, race, ethnicity, or gender. All donors were able to provide informed consent, or had a legal guardian or representative able to
do so. Study exclusion criteria included lack of willingness or ability to provide informed consent, or lack of an appropriate legal
guardian to provide informed consent.
Disease severity was defined asmild, moderate, severe or critical as previously described (Grifoni 2020).1 In brief, this classification
of disease severity is based on a modified version of the WHO interim guidance, ‘‘Clinical management of severe acute respiratory
infection when COVID-19 is suspected’’ (WHOReference Number: WHO/2019-nCoV/clinical/2020.4). At the time of enrollment in the
study, 80% of donors had been confirmed positive by swab test viral PCR during the acute phase of infection. Plasma samples from
all donors were later tested by IgG ELISA for SARS-CoV-2 S protein RBD to verify previous infection (Table S1; Figure 2A).
Healthy Unexposed donors utilized for CD4-E and CD8-E megapool validation
Samples from healthy adult donors were obtained from the San Diego Blood Bank (SDBB). According to the criteria set up by the
SDBB if a subject was eligible to donate blood, they were considered eligible for our study. All the donors were tested for SARS-
CoV-2 RBD IgG serology and were found negative and therefore considered unexposed. An overview of the characteristics of these
donors is provided in Table S1.
Convalescent COVID-19 donors utilized for CD4-E and CD8-E megapool validation
The 31 convalescent donors tested in themegapool AIM and FluoroSpot assays (Figure 7) were collected from the same clinics using
the same protocols as described above for the donors utilized for epitope identification. Similarly, no donors enrolled were under the
age of 18 and none were excluded due to disease severity, race, ethnicity, or gender. All donors, or legal guardians, gave informed
consent. Specific characteristics of these donors can be found in Table S3, including the summary of ELISA testing for SARS-CoV-
2 S protein RBD.
METHOD DETAILS
Peptide Pools
Preparation of 15-mers and subsequent megapools and mesopools
To identify SARS-CoV-2-specific T cell epitopes, 15-mer peptides overlapping by 10 amino acids and spanning entire SARS-CoV-2
proteins were synthesized. All peptides were synthesized as crude material (A&A, San Diego, CA) and individually resuspended in
dimethyl sulfoxide (DMSO) at a concentration of 10 mg/mL. Aliquots of these peptides were pooled by antigen of provenance into
megapools (MP) (as described in Table S3 and sequentially lyophilized as previously reported49. Another portion of the 15-mer pep-
tides were pooled into smaller mesopools of ten peptides each. All pools were resuspended at 1 mg/mL in DMSO.
Class I peptide preparation
Class I predicted peptides were designed using the protein sequences derived from the SARS-CoV-2 reference strain (GenBank:
MN908947). Predictions were performed as previously reported using NetMHC pan EL 4.0 algorithm46 for 28 HLA A and B alleles
that were selected based on frequency in our cohort and also representative of the worldwide population (Figures S1A and S1B).
The top 200 predicted peptides were selected for each allele. In total 5,600 class I peptides were synthesized and resuspended
in DMSO at 10 mg/mL.
PBMC isolation and HLA typing
Whole blood was collected from all donors in either Acid Citrate Dextrose (ACD) tubes or heparin coated blood bags. Whole blood
was then centrifuged at room temperature for 15 minutes at 1850 rpm to separate the cellular fraction and plasma. The plasma was
then carefully removed from the cell pellet and stored at20C. Peripheral bloodmononuclear cells (PBMC) were isolated by density-
gradient sedimentation using Ficoll-Paque (Lymphoprep, Nycomed Pharma) as previously described32. Isolated PBMC were cryo-
preserved in cell recovery media containing 10% DMSO (GIBCO), supplemented with 90% heat-inactivated fetal bovine serum,
depending on the processing laboratory, (FBS; Hyclone Laboratories, Logan UT) and stored in liquid nitrogen until used in the assays.Cell Reports Medicine 2, 100204, February 16, 2021 e2
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the class I HLA A and B loci and class II DRBI, DQB1, and DPB1 loci.
SARS-CoV-2 RBD ELISA
The SARS-CoV-2 RBD ELISA has been described in detail elsewhere.1 All convalescent COVID-19 donors had their serology deter-
mined by ELISA. Briefly, 96-well half-area plates (ThermoFisher 3690) were coated with 1 ug/mL SARS-CoV-2 Spike (S) Receptor
Binding Domain (RBD) and incubated at 4C overnight. On the following day plates were blocked at room temperature for 2 hours
with 3%milk in phosphate buffered saline (PBS) containing 0.05%Tween-20. Then, heat-inactivated plasmawas added to the plates
for another 90-minute incubation at room temperature followed by incubation with conjugated secondary antibody, detection, and
subsequent data analysis by reading the plates on Spectramax Plate Reader at 450 nm using SoftMax Pro. Limit of detection (LOD)
was defined as 1:3. Limit of sensitivity (LOS) for SARS-CoV-2 infected individuals was established based on uninfected subjects,
using plasma from normal healthy donors not exposed to SARS-CoV-2.
Flow Cytometry
Activation induced cell marker (AIM) assay
The AIM assay was performed as previously described25,50. Cryopreserved PBMCs were thawed by diluting the cells in 10 mL com-
plete RPMI 1640 with 5% human AB serum (Gemini Bioproducts) in the presence of benzonase [20 ml/10ml]. Cells were cultured for
20 to 24 hours in the presence of SARS-CoV-2 specific MPs [1 mg/ml], mesopools [1 mg/ml], 15-mers [10 mg/ml], or class I predicted
peptides [10 mg/ml] in 96-wells U bottom plates with 1x106 PBMC per well. As a negative control, an equimolar amount of DMSOwas
used to stimulate the cells as a negative control in triplicate wells, and phytohemagglutinin (PHA, Roche, 1 mg/ml) was included as the
positive control. The cells were stained with CD3 AF700 (4:100; Life Technologies Cat# 56-0038-42), CD4 BV605 (4:100; BD Biosci-
ences Cat# 562658), CD8 BV650 (2:100; Biolegend Cat# 301042), and Live/Dead Aqua (1:1000; eBioscience Cat# 65-0866-14). Acti-
vation was measured by the following markers: CD137 APC (4:100; Biolegend Cat# 309810), OX40 PE-Cy7 (2:100; Biolegend
Cat#350012), and CD69 PE (10:100; BD Biosciences Cat# 555531). All samples were acquired on either a ZE5 cell analyzer (Bio-
rad laboratories) or an Aurora flow cytometry system (Cytek), and analyzed with FlowJo software (Tree Star).
HLA binding assays
The binding of selected SARS-CoV-2 15-mer epitopes to HLA class II MHC molecules was measured as previously described (Sid-
ney 2013, Voic 2020).29 In brief, the binding is quantified by each peptide’s capacity to inhibit the binding of a radiolabeled peptide
probe to purified MHC in classical competition assays. The probe was incubated with purified MHC, a mixture of protease inhibitors,
and different concentrations of unlabeled inhibitor peptide at room temperature or 37C for 2 days. MHC molecules were subse-
quently captured onHLA-DR-specificmonoclonal antibody (L243) coated Lumitrac 600 plates (Greiner Bio-one, Frickenhausen, Ger-
many) and radioactivity was measured using the TopCount microscintillation counter (Packard Instrument Co., Meriden, CT). Each
peptide was tested at 6 concentrations to cover a 100,000-fold dose range, and an unlabeled version of the radiolabeled probe was
included in each experiment as a positive control for inhibition. To analyze the results, we calculated the concentration of peptide at
which the binding was inhibited by 50% (IC50 nM). For these values to approximate true Kd values, the following conditions weremet:
1) the concentration of radiolabelled probe is less than the concentration of MHC, and 2) themeasured IC50 is greater than or equal to
the concentration of MHC.
FluoroSpot
PBMCs derived from 25 unexposed donors were stimulated in triplicate at a single density of 200x103 cells/well (one donor was
tested at 50x103 due to limitation in cell numbers). PBMCs from a cohort of 31 convalescent COVID-19 donors were stimulated in
triplicates of 200x103 cells/well, with the exception of 5 donors tested at 50-100x103 cells/well due to cell limitations (Figures 7B,
7D, 7F, and 7H). Seventeen of these convalescent donors were further titrated at 200, 50, 25, and 12.5x103 cells/well (Figures 7I–
7L). The cells were stimulated with the different MPs analyzed (1mg/mL), PHA (10mg/mL), and DMSO (0.1%) in 96-well plates previ-
ously coated with anti-cytokine antibodies for IFNg, (mAbs 1-D1K; Mabtech, Stockholm, Sweden) at a concentration of 10mg/mL.
After 20 hours of incubation at 37C, 5% CO2, cells were discarded and FluoroSpot plates were washed and further incubated for
2 hours with cytokine antibodies (mAbs 7-B6-1-BAM; Mabtech, Stockholm, Sweden). Subsequently, plates were washed again
with PBS/0.05% Tween20 and incubated for 1 hour with fluorophore-conjugated antibodies (Anti-BAM-490). Computer-assisted im-
age analysis was performed by counting fluorescent spots using an AID iSPOT FluoroSpot reader (AIS-diagnostika, Germany). Each
megapool was considered positive compared to the background based on the following criteria: 20 or more spot forming cells (SFC)
per 106 PBMC after background subtraction for each cytokine analyzed, a stimulation index (S.I.) greater than 2, and statistically
different from the background (p < 0.05) in either a Poisson or t test.
QUANTIFICATION AND STATISTICAL ANALYSIS
FlowJo 10 and GraphPad Prism 8.4 were used to perform data and statistical analyses, unless otherwise stated. Statistical details of
the experiments are provided in the respective figure legends. Data plotted in linear scale are expressed as mean + standard devi-
ation (SD). Data plotted in logarithmic scales are expressed asmedian + 95%confidence interval (CI) or geometric mean + geometric
SD. Statistical analyses were performed using Spearman correlation and Mann-Whitney or Kolmogorov-Smirnov tests for unpaired
comparisons. Details pertaining to significance are also noted in the respective figure legends.e3 Cell Reports Medicine 2, 100204, February 16, 2021
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In analyzing data from the AIM assays, the counts of AIM+ CD4+ and CD8+ T cells were normalized based on the counts of CD4+ and
CD8+ T cells in each well to be equivalent to 1x106 total CD8+ or CD4+ T cells. The background was removed from the data by sub-
tracting the single or the average of the counts of AIM+ cells plated as single or triplicate wells stimulatedwith DMSO.We included the
triplicate wells stimulated with DMSO in the mesopools and epitope identification steps to take into account the variability of the
weaker signals observed in those two respect to the original MP reactivity24. The Stimulation Index (SI) was calculated by dividing
the count of AIM+ cells after SARS-CoV-2 stimulation with the ones in the negative control. A positive response had an SI greater
than 2 and a minimum of 100 AIM+ cells after background subtraction. The gates for AIM+ cells were drawn relative to the negative
and positive controls for each donor. A representative example of the gating strategy is depicted in Figure S3B.
HLA class I nested epitopes
For some alleles and proteins, multiple nested class I predicted peptides were tested in the AIM assay. In cases where a specific
donor responded to multiple nested epitopes corresponding to the same allele and protein, the epitope with the highest magnitude
of responsewas classified as the optimal epitope. If multiple nested epitopes had the same response (within a range of 50 AIM+ cells),
the epitope with the shortest length was selected. Nested epitopes corresponding to different donors or different alleles were
conserved as separate epitopes.
CCC homology analysis
SARS-CoV-2-derived 15-mer peptides were analyzed for their identity with the common cold coronaviruses (CCC) 229E, NL63,
HKU1, and OC43, as previously described15. In brief, every SARS-CoV-2 15-mer peptide tested for immunogenicity was compared
against every position in the corresponding protein sequences of common coronaviruses obtained from GenBank. The region that
best matched the respective SARS-CoV-2 peptide was used to calculate percent sequence identity for each of the four CCC viruses
individually, as well as the maximum across all four (Figure S5A). The same methodology was also used to calculate sequence iden-
tity for SARS-CoV-2 class I peptides (Figure S5B). Using the same set of common coronavirus reference sequences, an alternative
analysis was performed by mapping each SARS-CoV-2 peptide with the S, M and N protein sequences corresponding to the four
common coronavirus using Immunobrowser tool51. The values resulted from this specific analysis are plotted in Figure 5.
T cell epitope restriction predictions
Putative HLA class II restrictions for individual 15-mer CD4+ T cell epitopes were inferred using the IEDB’s TepiTool resource (Paul
2016). All CD4+ T cell prediction analyses were performed applying the NetMHCIIpan algorithm52. Prediction analyses were per-
formed to either infer HLA restriction based on the HLA typing of the cohort (Tables S2 and S5) or to assess potential binding pro-
miscuity of experimentally defined epitopes, considering the 27 most frequent class II alleles in the worldwide population21. In both
types of prediction analyses, a 20th percentile threshold was applied (Table S3), as previously described15.
Assigning regions within the linear structure
Simple diagramswere created to describe the linear structures of S, N, andMproteins (Figure 4). The different regions of the S protein
were defined based on the works of Cai et al., 2020.34 The structure of the N protein was divided into 3 main regions, the N- and
C-terminal domains, and the linker region in between53. For the M protein, the regions of the structure were extracted from UniProt
(UniProtKB - P59596 (VME1_SARS).
3D-rendering and model design
Three different approaches have been used tomap T andB cell immunodominant regions on the 3D-structures for SARS-CoV-2 S,M
and N proteins. The S protein model was based on the crystal structure described in Cai et al., 202034 (PDB: 6XR8) and using the
glycosylation sites annotated in the submitted PDB. The M protein model has been previously described by Heo et al., 2020. The
model for the Nprotein was run on four different homology prediction servers (SWISS-MODEL, RaptorX, iTasser and Phyre2). In order
to have a complete N sequence, Phyre2 server was subsequently selected using the intensivemode54. The resultingmodel showed a
variable level of confidence with higher percentages (> 90%) in the C-Terminal domain (CTD) and N-terminal domain (NTD) regions
and low confidence percentages (> 10%) in the linker domain. The N model was superimposable with both the crystal structures for
the CTD (PDB: 6WZO) and NTD (PDB: 6M3M). The current N model has the only purpose of visualization for mapping immunodo-
minant regions. All the mapping analyses have been performed using the free version of YASARA55.Cell Reports Medicine 2, 100204, February 16, 2021 e4
